Oric Pharmaceuticals Inc ORIC

$12.20 -0.32 (-2.52%)

Valuation

Market cap: 1,297,736,000
Revenue TTM: $0
Net income TTM: $-129,470,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 1,232,000
Avg volume: 1,493,596
Day's range: $12.16 – $12.93
Shares out: 103,653,000
Stochastic %K: 2%
Beta: 0.98
Analysts: Strong Sell
Price target: $20.64

Price

Company profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 388 5600
Website: https://www.oricpharma.com
Address: 240 E. Grand Ave, 2nd Floor, South San Francisco, United States

Latest news

Oct 2, 2026, 4:30 PM EDT · 1 day ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-09-23T10:10:34.000Z · 10 days ago

Oric Pharmaceuticals initiated with a Buy at BTIG

PFE

2026-09-23T10:05:10.000Z · 10 days ago

Oric Pharmaceuticals initiated with a Buy at BTIG

Sep 2, 2026, 4:05 PM EDT · 4 weeks ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-08-10T10:25:39.000Z · 7 weeks ago

Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright

2026-08-03T20:40:50.000Z · 2 months ago

Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c)

Aug 3, 2026, 4:05 PM EDT · 2 months ago

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Jul 20, 2026, 8:30 AM EDT · 2 months ago

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

2026-07-14T20:10:32.000Z · 2 months ago

Oric Pharmaceuticals initiates Himalayas-1 trial

Jul 14, 2026, 4:05 PM EDT · 2 months ago

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

2026-06-11T20:17:00.000Z · 3 months ago

Oric Pharmaceuticals resumed with a Buy at Stifel

2026-05-15T09:11:41.000Z · 4 months ago

Oric Pharmaceuticals moved to Buy rating at Goldman Sachs

2026-05-05T10:39:49.000Z · 5 months ago

Oric Pharmaceuticals price target lowered to $16 from $17 at Citi

2026-05-04T20:44:59.000Z · 5 months ago

Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)

May 4, 2026, 4:05 PM EDT · 5 months ago

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

2026-04-17T20:10:55.000Z · 5 months ago

Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR

Apr 17, 2026, 4:05 PM EDT · 5 months ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Apr 6, 2026, 8:06 AM EDT · 6 months ago

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-04-02T10:16:26.000Z · 6 months ago

Oric selloff brings attractive entry point, says H.C. Wainwright

2026-04-01T17:37:13.000Z · 6 months ago

Oric Pharmaceuticals should be bought on selloff, says Citi

2026-04-01T14:11:40.000Z · 6 months ago

Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush

PFE

2026-04-01T13:43:26.000Z · 6 months ago

Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald

PFE

2026-04-01T13:25:44.000Z · 6 months ago

Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch

2026-03-31T22:35:17.000Z · 6 months ago

Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update

Mar 31, 2026, 4:05 PM EDT · 6 months ago

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Mar 27, 2026, 8:30 AM EDT · 6 months ago

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Mar 17, 2026, 5:01 PM EDT · 6 months ago

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Feb 23, 2026, 4:05 PM EST · 7 months ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

Jan 12, 2026, 8:30 AM EST · 8 months ago

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

Jan 6, 2026, 4:05 PM EST · 9 months ago

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 8:00 PM EST · 10 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 1:00 AM EST · 10 months ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 4, 2025, 9:45 PM EST · 10 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Dec 3, 2025, 4:01 PM EST · 10 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 1, 2025, 8:00 AM EST · 10 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Nov 24, 2025, 4:05 PM EST · 10 months ago

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 4:10 PM EST · 10 months ago

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Nov 13, 2025, 4:05 PM EST · 10 months ago

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Nov 6, 2025, 4:00 PM EST · 11 months ago

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Oct 27, 2025, 8:30 AM EDT · 11 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

Aug 18, 2025, 4:05 PM EDT · 1 year ago

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

Aug 12, 2025, 4:05 PM EDT · 1 year ago

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

May 28, 2025, 4:05 PM EDT · 1 year ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT · 1 year ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 8:00 AM EDT · 1 year ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT · 1 year ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT · 1 year ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT · 1 year ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST · 1 year ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 18, 2025, 4:05 PM EST · 1 year ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Jan 13, 2025, 8:05 AM EST · 1 year ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST · 1 year ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST · 1 year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT · 1 year ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT · 1 year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 26, 2024, 4:05 PM EDT · 2 years ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT · 2 years ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT · 2 years ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 16, 2024, 4:59 PM EDT · 2 years ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT · 2 years ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT · 2 years ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT · 2 years ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 11, 2024, 4:05 PM EDT · 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Stocktwits

noturfinancrbro Sep 3, 3:42 PM

$ORIC looks nice

0 replies

Quantumup Aug 17, 11:36 AM

H.C. Wainwright⬆️ $AVBP's PT to $47 and reiterated Buy. $CGON $ORIC JNJ AZN SMMT BDTX Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2089314943409574282?s=20

0 replies

Quantumup Aug 10, 12:04 PM

H.C. Wainwright⬆️ $ORIC's PT to $27 from $25 and reiterated at Buy. $PFE $VIR JNJ IPSEY DSNKY AVBP CGEM AZN Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2086785654541738231?s=20

0 replies